BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34589381)

  • 1. Histological Tracking into the Third Dimension: Evolution of Early Tumorigenesis in VHL Kidney.
    Mubarak M; Al-Gharaibeh N; Sommaruga S; Li J; Vortmeyer AO
    J Kidney Cancer VHL; 2021; 8(3):5-14. PubMed ID: 34589381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Microscopic Multicellular Foci in Grossly Normal Renal Parenchyma of Von Hippel-Lindau Kidney.
    Al-Gharaibeh NS; Shively SB; Vortmeyer AO
    Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556926
    [No Abstract]   [Full Text] [Related]  

  • 3. Progression of epididymal maldevelopment into hamartoma-like neoplasia in VHL disease.
    Mehta GU; Shively SB; Duong H; Tran MG; Moncrief TJ; Smith JH; Li J; Edwards NA; Lonser RR; Zhuang Z; Merrill MJ; Raffeld M; Maxwell PH; Oldfield EH; Vortmeyer AO
    Neoplasia; 2008 Oct; 10(10):1146-53. PubMed ID: 18813354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nervous system involvement in von Hippel-Lindau disease: pathology and mechanisms.
    Vortmeyer AO; Falke EA; Gläsker S; Li J; Oldfield EH
    Acta Neuropathol; 2013 Mar; 125(3):333-50. PubMed ID: 23400300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease.
    Montani M; Heinimann K; von Teichman A; Rudolph T; Perren A; Moch H
    Am J Surg Pathol; 2010 Jun; 34(6):806-15. PubMed ID: 20431476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis.
    Decker HJ; Weidt EJ; Brieger J
    Cancer Genet Cytogenet; 1997 Jan; 93(1):74-83. PubMed ID: 9062583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vhl deletion in renal epithelia causes HIF-1α-dependent, HIF-2α-independent angiogenesis and constitutive diuresis.
    Schönenberger D; Rajski M; Harlander S; Frew IJ
    Oncotarget; 2016 Sep; 7(38):60971-60985. PubMed ID: 27528422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
    Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
    Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the Von Hippel-Lindau tumor suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis.
    Kessler PM; Vasavada SP; Rackley RR; Stackhouse T; Duh FM; Latif F; Lerman MI; Zbar B; Williams BR
    Mol Med; 1995 May; 1(4):457-66. PubMed ID: 8521303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma.
    Schraml P; Struckmann K; Hatz F; Sonnet S; Kully C; Gasser T; Sauter G; Mihatsch MJ; Moch H
    J Pathol; 2002 Feb; 196(2):186-93. PubMed ID: 11793370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
    Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
    Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters.
    Kondo K; Yao M; Yoshida M; Kishida T; Shuin T; Miura T; Moriyama M; Kobayashi K; Sakai N; Kaneko S; Kawakami S; Baba M; Nakaigawa N; Nagashima Y; Nakatani Y; Hosaka M
    Genes Chromosomes Cancer; 2002 May; 34(1):58-68. PubMed ID: 11921283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells.
    Sutphin PD; Chan DA; Li JM; Turcotte S; Krieg AJ; Giaccia AJ
    Cancer Res; 2007 Jun; 67(12):5896-905. PubMed ID: 17575159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
    Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
    Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME.
    Tedesco L; Elguero B; Pacin DG; Senin S; Pollak C; Garcia Marchiñena PA; Jurado AM; Isola M; Labanca MJ; Palazzo M; Yankilevich P; Fuertes M; Arzt E
    Cell Death Dis; 2019 Mar; 10(4):266. PubMed ID: 30890701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α.
    Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ
    Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.
    Fan Y; Li H; Ma X; Gao Y; Bao X; Du Q; Ma M; Liu K; Yao Y; Huang Q; Zhang Y; Zhang X
    Oncotarget; 2016 Apr; 7(14):18280-94. PubMed ID: 26943772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.